Remission of Cushing’s disease associated with higher risk of developing autoimmune disease

Embargoed for release until 5:00 p.m. ET on Monday 19 February 2024   
Annals of Internal Medicine Tip Sheet    

@Annalsofim   
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, but also on behalf of the organization they represent.   
----------------------------   

Remission of Cushing’s disease associated with higher risk of developing autoimmune disease 

Abstract: https://www.acpjournals.org/doi/10.7326/M23-2024  

URL goes live when the embargo lifts    

A study of more than 250 persons undergoing surgical therapy for Cushing’s disease (CD) or nonfunctioning pituitary adenomas (NFPAs) found that patients who achieved remission of CD were more likely than those with surgically treated NFPAs to develop new-onset autoimmune disease within 3 years after remission. The study is published in Annals of Internal Medicine. 

CD results from excessive production of corticotropin (ACTH) by a pituitary adenoma, which causes hypercortisolemia. Transsphenoidal surgery (TSS) is the first-line treatment for most hypersecreting pituitary adenomas. After TSS for CD, adrenal insufficiency occurs once the ACTH-secreting tumor is removed, the signs and symptoms of hypercortisolemia typically improve over time but steroid withdrawal symptoms may develop after remission of CD. In addition, the development of new autoimmune disease in patients after CD remission has been observed, but research is limited. 

Researchers from Harvard Medical School identified 194 persons with CD and 92 persons with NFPA, frequency-matched for age and sex, who underwent pituitary surgery. The authors found that persons with CD who achieved remission were more likely than those with surgically treated NFPAs to develop new-onset autoimmune disease within 3 years after remission. The cumulative incidence was 10.4 percent. According to the authors, higher prevalence of adrenal insufficiency and the lower nadir serum cortisol levels in the CD group suggest that the postoperative adrenal insufficiency might have contributed to the development of autoimmune diseases. They also note that patients with CD who have a family history of autoimmune disease should be carefully monitored after achieving remission. In addition, the authors add that higher doses of early postoperative glucocorticoid replacement might be associated with decreased risk for development of autoimmune disease. These findings have implications for the understanding of the natural history of autoimmune disease and its relationship to cortisol fluctuations.

Media contacts: For an embargoed PDF, please contact Angela Collom at acollom@acponline.org. To speak with the corresponding author, Lisa B. Nachtigall, MD, please contact Lisa Nachtigall, MD at  lnachtigall@mgh.harvard.edu.  

---------------------------- 

Also new in this issue: 

Responding to Reviewers and Editors Regarding Statistical Significance Testing 

David A. Savitz, PhD; Lauren A. Wise, MSc, ScD; Julia C. Bond, MPH; Elizabeth E. Hatch, MS, PhD; Collette N. Ncube, DrPH, MPH, MS; Amelia K. Wesselink, PhD; Mary D. Willis, PhD, MPH; Jennifer J. Yland, PhD; Kenneth J. Rothman, DrPH 

Ideas and Opinions 

Abstract: https://www.acpjournals.org/doi/10.7326/M23-2430